v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue:    
Research and development $ 33,333
Costs and Expenses:    
Research and development 4,978,105 3,241,432
General and administrative 2,744,195 3,145,010
Total costs and expenses 7,722,300 6,386,442
Loss from operations (7,722,300) (6,353,109)
Sale of New Jersey net operating loss & tax credits 1,734,133 1,328,470
Other income, net 9,894 68,319
Net loss (5,978,273) (4,956,320)
Preferred stock series B accumulated dividends (210,900)
Net loss attributable to common shareholders $ (5,978,273) $ (5,167,220)
Net loss attributable to common shareholders per share - basic and diluted $ (0.03) $ (0.03)
Weighted average common shares outstanding:    
Basic and diluted 216,644,783 203,871,820
Other comprehensive loss, net of tax    
Unrealized loss on securities available-for-sale $ (483,675) $ (91,766)
Other comprehensive loss, net of tax (483,675) (91,766)
Comprehensive loss attributable to shareholders $ (6,461,948) $ (5,048,086)

Source